Neurologists Robert Bermel, MD; Rebecca Cebull, CNP; and Marisa McGinley, DO, discuss where serum neurofilament light and GFAP fit into MS care today and why the field is still waiting on a biomarker ...
Overall, fluctuating symptom control was the most commonly cited reason for discontinuing a prior therapy, identified by 57% of providers, while preference for a consistent treatment schedule was the ...
Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...
The FDA was busy in September 2026, issuing a number of decisions on potential new therapies, including approvals, clearances ...
Former NASCAR driver Darrell Waltrip recently announced a diagnosis of frontotemporal dementia (FTD). Waltrip, a 3-time ...
Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a ...
With two on-label agents now available, the panel turns to what actually drives the choice between them, noting how recently ...
Neurology moves fast, and the assumptions that shape how we practice do not always keep up. Gray Areas is a NeurologyLive ...
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
Congressional passage would extend ACT for ALS programs and associated research grants through FY2031, sustaining federal ...
Cerebral palsy (CP) is the most common motor disability of childhood, a group of permanent movement disorders caused by a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results